Insulin aspart
Fiasp, Novolog, NovoMix, NovoRapid (insulin aspart) is a protein pharmaceutical. Insulin aspart was first approved as Fiasp on 1999-09-07. It has been approved in Europe to treat diabetes mellitus.
| Trade Name | Fiasp, NovoMix, NovoRapid |
|---|---|
| Common Name | Insulin aspart |
| Indication | diabetes mellitus |
| Drug Class |
